HDL cholesterol: A new target in the treatment of lipid disorders and atherosclerosis?;El colesterol HDL: ¿un nuevo objetivo terapéutico en el manejo de las dislipidemias y la ateroesclerosis?

Revista Medica de Chile

Volumn 133, Issue 7, 2005, Pages 823-832

  Del Rosario Laris E, María ^a   Arteaga L, Antonio ^a   Cuevas M, Ada ^b   Rigotti R, Attilio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b CLÍNICA LAS CONDES   (Chile)

Author keywords

Atherosclerosis; Cardiovascular diseases; Lipoproteins, HDL cholesterol

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD; DYSLIPIDEMIA; HUMAN; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; DYSLIPIDEMIAS; HUMANS; RISK FACTORS;

EID: 27744451182     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. MASCIE-TAYLOR CG, KARIM E. The burden of chronic disease. Science 2003; 302: 1921-2.
2. THOMPSON GR, BARTER PJ. Clinical lipidology at the end of the millennium. Curr Opin Lipidol 1999; 10: 521-6.
3. BARTER PJ, RYE KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1-12.
4. GORDON DJ, RIFKIND BM. High-density lipoprotein, the clinical implications of recent studies. N Engl J Med 1989; 321: 1311-6.
5. SCHAEFER EJ. Familial lipoprotein disorders and premature coronary artery disease. Med Clin North Am 1994; 78: 21-39.
6. KWITEROVICH PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82: 13Q-21Q.
7. BREWER HB JR, SANTAMARINA-FOJO S. Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. Am J Cardiol 2003; 92: 10K-16K
8. JOYCE C, FREEMAN L, BREWER HB JR, SANTAMARINA-FOJO S. Study of ABCA1 function in transgenic mice. Arterioscler Thromb Vasc Biol 2003; 23: 965-71.
9. PEELMAN F, VANDEKERCKHOVE J, ROSSENEU M. Structure and function of lecithin cholesterol acyltransferase: new insights from structural predictions and animal models. Curr Opin Lipidol 2000; 11: 155-60.
10. TALL AR, JIANG X, LUO Y, SILVER D. Lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 1185-8.
11. CUEVAS A, ALVAREZ V, ACOSTA AM, ALTAYO M, MONTERO J, RIGOTTI A. Mecanismos de hipo e hiperalfalipoproteinemia en individuos adultos chilenos. Rev Méd Chile 2004; 132: 421-8.
12. BARTER PJ, BREWER HB JR, CHAPMAN MJ, HENNEKENS CH, RADER DJ, TALL AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-7.
13. PITTMAN RC, STEINBERG D. Sites and mechanisms of uptake and degradation of high density and low density lipoproteins. J Lipid Res 1984; 25: 1577-785.
14. LEBLOND L, MARCEL YL. Uptake of high density lipoprotein cholesterol ester by HepG2 cells involves apolipoprotein E localized on the cell surface. J Biol Chem 1993; 268: 1670-6.
15. GARCÍA A, BARBARAS R, COLLET X, BOGYO A, CHAP H, PERRET B. High density lipoprotein 3 receptor-dependent endocytosis pathway in a human hepatoma cell line (HepG2). Biochemistry 1996; 35: 13064-71.
16. GOLDBERG DI, BELTZ WF, PITTMAN RC. Evaluation of pathways for the cellular uptake of high density lipoprotein cholesterol esters in rabbits. J Clin Invest 1991; 87: 331-46.
17. ACTON S, RIGOTTI A, LANDSCHULZ KT, XU S, HOBBS HH, KRIEGER M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518-20.
18. RIGOTTI A, KRIEGER M. Getting a handle on "good" cholesterol with the high-density lipoprotein receptor. N Engl J Med 1999; 341: 2011-3.
19. RIGOTTI A, MIETTINEN HE, KRIEGER M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24: 357-87.
20. TRIGATTI BL, KRIEGER M, RIGOTTI A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1732-8.
21. BRAUN A, TRIGATTI BL, POST MJ, SATO K, SIMONS M, EDELBERG JM ET AL. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002; 90: 270-6.
22. RADER DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003; 92: 42J-49J.
23. SACKS FM; EXPERT GROUP ON HDL CHOLESTEROL. The role of high density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139-43.
24. SACKS FM. The relative role of low density lipoprotein cholesterol and high density lipoprotein cholesterol in coronary artery disease: evidence from large scale statin and fibrate trials. Am J Cardiol 2001; 88: 14N-18N.
25. RUBINS HB, ROBINS SJ, COLLINS D, FYE CL, ANDERSON JW, ELAM MB ET AL. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Eng J Med 1999; 341: 410-8.
26. RUBINS HB, ROBINS SJ. Conclusions from the VAHIT study. Am J Cardiol 2000; 86: 543-4.
27. THE BIP (BENZAFIBRATO INFARCTION PREVENTION) STUDY GROUP. Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Heart Disease. Circulation 2000; 102: 21-7.
28. NISSEN SE, TSUNODA T, TUZCU EM, SCHOENHAGEN P, COOPER CJ, YASIN M ET AL. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
29. ERIKSSON M, CARLSON LA, MIETTINEN TA, ANGELIN B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100: 594-8.
30. NANJEE MN, COOKE CJ, GARVIN R, SEMERIA F, LEWIS G, OLSZEWSKI WL ET AL. Intravenous apo A-I/lecithin discs increase pre beta HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001; 42: 1586-93.
31. RADER DJ. High density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA 2003; 290: 2322-4.
32. DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF, DE GRAAF J, ZWINDERMAN AH, POSMA JL ET AL. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105: 2159-65.
33. CLARK RW, SUTFIN TA, RUGGERI RB, WILLAUER AT, SUGARMAN ED, MAGNUS-ARYITEY G ET AL. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24: 490-7.
34. BROUSSEAU ME, SCHAEFER EJ, WOLFE ML, BLOEDON LT, DIGENIO AG, CLARK RW ET AL. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-15.
35. BREWER HB JR. Increasing HDL Cholesterol Levels. N Engl J Med 2004; 350: 1491-4.
36. RIGOTTI A. Los receptores nucleares como nuevas dianas terapéuticas para un manejo integral de las dislipidemias. Clin Invest Arterioscl 2003; 15: 156-63.
37. LAZAR MA. Progress in cardiovascular biology: PPAR for the course. Nat Med 2001; 7: 23-4.
38. REPA JJ, TURLEY SD, LOBACCARO JMA, MEDINA J, LI L, LUSTIG K et al. Regulation of absorption and ABC1 mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-9.
39. OLIVER W, SHENK J, SNAITH , RUSSELL C, PLUNKET K, BODKIN N ET AL. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-11.
40. LUO Y, TALL AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000; 105: 513-20.
41. MALEROD L, JUVET LK, HANSSEN-BAUER A, ESKILD W, BERG T. Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Commun 2002; 299: 916-23.
42. MILLATT LJ, BOCHER V, FRUCHART JC, STAELS B. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim Biophys Acta 2003; 1631: 107-18.
43. RICOTE M, VALLEDOR AF, GLASS CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 230-9.
44. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988; 148: 36-69.
45. GRUNDY SM, GOODMAN DW, RIFKIND BM, CLEEMAN JI. The place of HDL in cholesterol management. A perspective from the National Cholesterol Educational Program. Arch Intern Med 1989; 149: 505-10.
46. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
48. ROSENSON RS. Low levels of high-density lipoprotein cholesterol (hypoalphalipoproteinemia). An approach to management. Arch Intern Med 1993; 153: 1528-38.
49. VEGA GL, GRUNDY SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996; 7: 209-16.
50. HARPER CR, JACOBSON TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999; 159: 1049-1045
51. RADER DJ. Pathophysiology and management of low high-density lipoprotein cholesterol. Am J Cardiol 1999; 83: 22F-24F.
52. RADER DJ, ROSAS S. Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation. Med Clin North Am 2000; 84: 43-6.
53. CIVEIRA F, GONZALVO C. Tratamiento del colesterol HDL bajo. Clin Invest Arterioscl 2000; 12: 209-11.
54. WATTS GF. Treating patients with low high density lipoprotein cholesterol: choices, issues and opportunities. Curr Control Trials Cardiovasc Med 2001; 2: 118-22.
55. TOTH PP. High density lipoprotein and cardiovascular risk. Circulation 2004; 109: 1809-12.